Comparative effectiveness of pioglitazone and sitagliptin added to metformin and sulfonylurea in patients with type 2 diabetes: An emulated target trial.

Authors

Tae Hyeon Kim, Yerin Hwang, Selin Woo, Kyeongmin Lee, Yejun Son, Seoyoung Park, Hyunjee Kim, Ju-Young Shin, YongHyun Cho, Dahye Shin, Dosang Cho, Kyung-Jae Lee, Chang Hyun Kim, Sang Youl Rhee, Dong Keon Yon

Published in

Medicine. Volume 105. Issue 34. Pages e50241. Aug 21, 2026.

Abstract

Dipeptidyl peptidase-4 inhibitors and thiazolidinediones are commonly used as add-ons in type 2 diabetes mellitus (T2DM) treatment, but comparative data are limited. This study emulated a target trial to compare sitagliptin and pioglitazone in patients on metformin and sulfonylurea, focusing on changes in glycemic control and clinical outcomes. This emulated target trial comprised 68,372 patients with T2DM identified from 4 university hospitals in South Korea (2001-2024). Patients with T2DM receiving both metformin and sulfonylurea were included and assigned to groups receiving either pioglitazone or sitagliptin as add-on therapy using 1:1 propensity score matching. Clinical indicators, including glycemic parameters, were evaluated for differences between groups using unpaired t-tests during the 24-week follow-up. To assess the possibility of achieving intensive glycemic control (HbA1c < 6.5%), Cox proportional hazards analysis was performed, reporting adjusted hazard ratio (aHR) with 95% confidence intervals (CIs). Following 1:1 propensity score matching, 1742 participants were assigned to each of the pioglitazone (mean age, 58.75 years; 64.7% male) and sitagliptin (mean age, 58.95 years; 64.7% male) groups. Both pioglitazone and sitagliptin reduced HbA1c over 24 weeks with no significant between-group difference (pioglitazone: -0.48% [95% CI, -0.55 to -0.41]; sitagliptin: -0.55% [95% CI, -0.61 to -0.48]; P-value = .182 for the between-group difference). However, sitagliptin was associated with a higher possibility of achieving HbA1c < 6.5% (aHR, 1.28 [95% CI, 1.08-1.53]), and showed greater reductions in body weight (pioglitazone: 0.26 kg [95% CI, -0.37 to 0.89]; sitagliptin: -0.91 kg [95% CI, -1.65 to -0.17]; P-value = .018 for the between-group difference) and LDL cholesterol (pioglitazone: -2.22 mmol/L [95% CI, -7.41 to 2.96]; sitagliptin: -11.42 mmol/L [95% CI, -16.95 to -5.89]; P-value = .017 for the between-group difference). Our findings suggest that sitagliptin showed more favorable metabolic profiles and a higher likelihood of achieving intensive glycemic targets compared with pioglitazone, beyond average glycemic control.

PMID:
42629678
Bibliographic data and abstract were imported from PubMed on 22 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.